Head-To-Head Survey: Celcuity (NASDAQ:CELC) vs. GeneLink (OTCMKTS:GNLKQ)

GeneLink (OTCMKTS:GNLKQ) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for GeneLink and Celcuity, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneLink	0	0	0	0	0.00
Celcuity	0	0	6	1	3.14

Celcuity has a consensus target price of $29.17, indicating a potential upside of 155.40%. Given Celcuity’s stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than GeneLink.

Profitability

This table compares GeneLink and Celcuity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneLink	N/A	N/A	N/A
Celcuity	N/A	-62.66%	-39.78%

Valuation and Earnings

This table compares GeneLink and Celcuity”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneLink	N/A	N/A	N/A	N/A	N/A
Celcuity	N/A	N/A	-$63.78 million	($2.61)	-4.38

Institutional & Insider Ownership

63.3% of Celcuity shares are held by institutional investors. 14.2% of GeneLink shares are held by insiders. Comparatively, 15.8% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Celcuity beats GeneLink on 6 of the 8 factors compared between the two stocks.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.